www.psych.uic.edu

Articles

Monsheel Sodhi B.Pharm, M.Sc., Ph.D.

Simpson
CONTACT INFORMATION
900 S Ashland Avenue
MBRB Rm. 3102, mc 870,
Chicago, IL 60607
Office Phone:312-355-5949
E-mail:This email address is being protected from spambots. You need JavaScript enabled to view it. 
KEY PUBLICATIONS

Sodhi MS, Arranz MJ, Curtis DA, Sham PC, Ball DM, Roberts GW,  et al. (1995):  Association between clozapine response and allelic variation in the 5-HT2C receptor gene.  NeuroReport 7: 369-375. PMID: 8742444 [Original research]

Arranz MJ, Collier D, Sodhi MS, Ball DM, Roberts GW, Price J, et al. (1995): Association between clozapine response and allelic variation in the 5-HT2A receptor gene. Lancet, 346: 281-282. PMID: 7630250 [Original research]

Collier D, Arranz M, Sham P, Battersby S, Gill P, Aitchison KJ, Sodhi MS, et al. (1996): The serotonin transporter is a potential susceptibility factor for bipolar affective disorder. NeuroReport 7:1675-1679. PMID: 8904780 [Original research]

Sodhi, M.S., and Murray, R.M. (1997). Future therapies for schizophrenia. Expert Opinion on Therapeutic Patents 7, 151165. [Review]

Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi MS, et al. (2000): Pharmacogenetic prediction of clozapine response. Lancet 355: 1615 - 1616. PMID: 10821369 [Original research]

Sodhi MS, Burnet PJ, Makoff AJ and Harrison PJ.(2001): Reduced mRNA editing of the human 5-HT2C receptor in schizophrenia. Molecular Psychiatry, 6 (4), 373-9. PMID: 11443520 [Original research] 

Pooley, E, Fairburn C, COOPER, z, Sodhi MS, Harrison, PJ. (2004) A 5-HT2C receptor promoter polymorphism (HTR2C - 759C/T) is associated with obesity in women, and with resistance to weight loss in heterozygotes. Am J Med Genet (Neuropsychiat Genet). 126B: 124-7.  PMID: 15048662 [Original research]

Tunbridge, E., P. W. Burnet, Sodhi MS, Harrison PJ (2004). "Catechol-o-methyltransferase (COMT) and proline dehydrogenase (PRODH) mRNAs in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression." Synapse 51(2):112-8.  PMID: 14618678 [Original research]

Sodhi, M.S., and SandersBush, E. (2004). Serotonin and brain development. International review of neurobiology 59, 111174. PMID:15006487 [review]

Sodhi MS, Airey D, Lambert W, Burnet PWJ, Harrison PJ and Sanders-Bush E. (2005) A rapid new assay to detect RNA editing reveals antipsychotic-induced changes in serotonin-2C transcripts. Mol Pharmacol 68: 711-719.[Original research] PMID: 15917433

Hackler E, Airey D, Shannon C, Sodhi MS, Sanders-Bush E (2006): 5-HT2C receptor RNA editing in the amygdala of inbred strains: implications for anxiety and fear. Neurosci Res 55(1):96-104. PMID: 16580757 [Original research]

Sodhi MS, Wood KH, Meador-Woodruff J (2008).  Role of glutamate in schizophrenia: integrating excitatory avenues of research. Expert Review of Neurotherapeutics  8(9): 1389-1406. PMID:18759551 [review]

Roth T, Lubin F, Sodhi MS and Kleinman J E(2009). Epigenetics and schizophrenia. Biochim Biophys Acta;1790(9):869-77. PMID: 19559755 [Review]Times cited=37

Simmons, M, Meador-Woodruff, J, Sodhi MS (2010). “Increased cortical expression of an RNA editing enzyme occurs in major depressive suicide victims.” Neuroreport 21(15): 993-7. PMID: 20802353 [original research]

Sodhi MS, Simmons M, McCullumsmith RE, Haroutunian V., MeadorWoodruff, J. (2011). Glutamatergic gene expression is specifically reduced in thalamocortical projecting relay neurons in schizophrenia. Biological Psychiatry 70:646–654. PMID: 21549355 [original research]

Bostrom JA, Sodhi MS. (2013) A Look to the Future: Epigenetics in Psychiatric Disorders and Treatment. In:  Lam YWF, Cavallari LH (eds). Pharmacogenomics:  Challenges and Opportunities in Therapeutic Implementation. Elsevier Inc:  Maryland Heights, MO. [Book chapter] p.225-246.

Hanson R, Gannon M, Khamo N, Sodhi MS, Orr A, Stubbings J (2013). Improvement in Safety Monitoring of Biologic Response Modifiers After the Implementation of Clinical Care Guidelines by a Specialty Pharmacy Service in an Academic Health System. Journal of Managed Care Pharmacy, 19 (1): 49-67. PMID: 23383700 [original research]

Monsheel Sodhi B.Pharm, M.Sc., Ph.D.

Assistant Professor

Dr. Monsheel Sodhi is an Assistant Professor in the Department of Pharmacy Practice, the Department of Psychiatry, the Center for Pharmaceutical Biotechnology and the Graduate Program in Neuroscience. She is also Director of the UIC Brain Collection. Dr. Sodhi’s laboratory has a longstanding commitment to translate discoveries from molecular neuroscience to improve our understanding and treatment of schizophrenia and mood disorders.

Lab/Research Program website: https://www.uic.edu/labs/sodhilab/ 

Dr. Sodhi received her degree in Pharmacy at the UCL School of Pharmacy at the University of London (U.K.). She subsequently achieved a Master’s degree in Neuroscience and a Ph.D. in Biochemistry at the Institute of Psychiatry and Maudsley Hospital at Kings College London. Her postdoctoral training, funded by a Medical Research Council training fellowship, was in Molecular Pathology at the Department of Psychiatry at Oxford University, and in Molecular Pharmacology at Vanderbilt University. Prior to joining the faculty at the University of Illinois at Chicago in 2011, she was a faculty member of the Department of Psychiatry and Comprehensive Neuroscience Center at UAB.

Dr. Sodhi has received two young investigator awards from the National Alliance for Research in Schizophrenia and Depression, an award from the American Foundation for Suicide Prevention and a young investigator award from the American College of Neuropsychopharmacology. She has also received Scholar’s Awards from the Health Services Foundation and the Hans W. Vahlteich Research Fund. Dr. Sodhi has over 15 years’ experience in the field of molecular neuroscience, including published work in the Lancet, Molecular Psychiatry, Molecular Pharmacology and Biological Psychiatry. She serves on the Editorial Boards of the Journal of Addiction and Neuropharmacology and the Austin Journal of Pharmacology & Therapeutics and as a member of the Tissue Review Panel of the NSW Brain Bank.

Interests:

• Molecular genetic and transcriptional abnormalities underpinning the pathophysiology of psychiatric disorders

• Pharmacogenomics and pharmaco-epigenomics of psychotropic drugs

• The mechanisms of psychotropic drug efficacy and side-effects • Neural circuit deficits in schizophrenia and mood disorders

• Developing and maintaining postmortem psychiatric brain collections

Affiliations/Memberships:

Society for Biological Psychiatry, Society for Neuroscience, General Pharmaceutical Council (UK), American Association of Colleges of Pharmacy. 

Projects:

• The impact of RNA editing on suicide risk.

• Glutamatergic abnormalities in major psychiatric disorders.

 

You are here: Home